Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.

But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

Against the odds GSK’s Dreamm-7 study yields a positive survival readout.

The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.